Chen Zhang

Chen Zhang

Auto-generated profile, based on publicly available information

Chen Zhang

Department of Rheumatology, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2024 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
CZChen Zhang
Chen Zhang
SLSiyi Lu
Siyi Lu
TKTianlun Kang
Tianlun Kang
FMFanzhang Meng
Fanzhang Meng
TQTangliang Qian
Tangliang Qian
XHXiujuan Hou
Xiujuan Hou

1 October 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
CZChen Zhang
Chen Zhang
TKTianlun Kang
Tianlun Kang
TQTangliang Qian
Tangliang Qian
MMMingwei Ma
Mingwei Ma
XHXiujuan Hou
Xiujuan Hou
CLChen Li
Chen Li
Secukinumab, a monoclonal antibody targeting interleukin-17 (IL-17), has exhibited encouraging results in the therapeutic management of palmoplantar pustulosis (PPP). The development of alopecia areata (AA) is closely related to IL-17, and IL-17A inhibitors were considered as a potential treatment modality. Therefore, the development of AA during secukinumab treatment for PPP is a rare adverse event that has been rarely reported worldwide. Here we report a 35-year-old female patient with PPP who developed AA after completing the induction period of secukinumab treatment. Discontinuing secukinumab and initiating treatment with tofacitinib resulted in a significant improvement in both PPP and AA. The emergence of AA in this patient can be attributed to paradoxical skin reactions associated with IL-17 inhibitors. Tofacitinib appears to alleviate biologic-induced AA during PPP syndrome treatment.

10 July 2024 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
FMFanzhang Meng
Fanzhang Meng
SLSiyi Lu
Siyi Lu
YLYingzi Li
Yingzi Li
CZChen Zhang
Chen Zhang
TKTianlun Kang
Tianlun Kang
XHXiujuan Hou
Xiujuan Hou

1 April 2025 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
QGQinchen Gu
Qinchen Gu
CZChen Zhang
Chen Zhang
ZLZhimin Lin
Zhimin Lin
YFYiting Fu
Yiting Fu
CLChen Li
Chen Li
ZYZhenhua Ying
Zhenhua Ying
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease with recurrent erythema, scales, and sterile pustules on the palms and soles. Treating PPP in children is difficult due to limited effective therapies, especially as there’s a lack of data on upadacitinib use in children under 12.This article reports a pediatric PPP case. The patient had severe, recurring rashes that affected daily activities. Treated with upadacitinib for two months, she showed a significant therapeutic response.

3 March 2025 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
QGQinchen Gu
Qinchen Gu
CZChen Zhang
Chen Zhang
WSWei Song
Wei Song
ZLZhimin Lin
Zhimin Lin
CLChen Li
Chen Li
ZYZhenhua Ying
Zhenhua Ying

13 November 2023
Verified
Preprint
Open access
PDF file
CZChen Zhang
Chen Zhang
XSXiaojun Shi
Xiaojun Shi
TQTangliang Qian
Tangliang Qian
XLXiaoping Liu
Xiaoping Liu
YDYihang Ding
Yihang Ding
CLChen Li
Chen Li
Tofacitinib, an oral Janus kinase inhibitor, has demonstrated teratogenic effects in animal models. However, there is a lack of data on its effects during human pregnancy, especially in the context of synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome, a rare disease. We report a case of a 31-year-old female patient with SAPHO syndrome who became pregnant unexpectedly after 5 weeks of continuous tofacitinib treatment during the first trimester. Tofacitinib was immediately discontinued upon discovering the pregnancy. The patient successfully delivered a healthy full-term male infant under vigilant monitoring, and her SAPHO syndrome symptoms ameliorated during gestation but exacerbated 40 days postpartum. Given the limited clinical data available, further monitoring of pregnancy outcomes in patients treated with tofacitinib is still warranted.